Toggle light / dark theme

Biotech startup Lucy Therapeutics is developing mitochondrial-based small molecule therapies for neurological diseases and recently revealed the first two drugs to emerge from its lead programme targeting Parkinson’s. The company, which takes its name from the 3.2-million-year-old fossil of an ancestor of humankind, presented “promising preclinical data” at the Michael J Fox Foundation’s Parkinson’s Disease Therapeutics Conference in October.

The data shown by Lucy Therapeutics demonstrated that its compounds were able to reverse mitochondrial dysfunctions linked to Parkinson’s. In cellular models of the disease, the drugs boosted levels of cellular energy molecule ATP, prevented the death of neurons, and reduced levels of other hallmarks of Parkinson’s, including a-synuclein.

Longevity. Technology: Mitochondria are widely known as the ‘power generators’ within our cells, and their dysfunction has been linked to a range of age-related diseases. But the role of mitochondria extends beyond cellular energy as they also dictate many of a cell’s key functions. Lucy Therapeutics was founded on the hypothesis that diseases with rate-limiting steps involving mitochondrial dysfunction can potentially be treated by modulating key mitochondrial protein targets. To find out more, we caught up with the company’s founder and CEO, Dr Amy Ripka.

BioAge Labs, a clinical-stage biotech developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ.

BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest.

Longevity. Technology: Muscle atrophy – loss of muscle mass and strength – is a universal feature of human aging that increases the risk of multiple morbidities, shortens lifespan and diminishes quality of life. Hospitalisation and periods of forced inactivity greatly accelerate this loss in older people.

Spermidine is a popular longevity supplement – and with good reason, as it has antiaging properties and can suppress inflammation and oxidation. Studies have shown the interestingly-named polyamine can increase lifespan in animal models, and research indicates that its decline with aging is linked to the onset of age-related diseases.

Longevity. Technology: All this background is useful if you are wondering if supplements are right for you and if so, which ones to take. However, having a professional perspective is always useful, and founder of Impact Health Dr Halland Chen MD is a Double Board-Certified doctor who is a Partnered Practitioner of spermidineLIFE. We caught up with Dr Chen to find out what it is like practising at the cutting edge of longevity medicine, and what are some of the most promising interventions he recommends to his patients.

I did a lot of things in the sports realm and I became very involved in regenerative medicine – which naturally leads to longevity. A large part of what I wanted to focus on was not just treating a symptom, but getting to the root cause. Longevity is more than antiaging and wellness – it’s about helping people heal. Nowadays, there is more we can do – it’s very much functional medicine; functional longevity, wellness… we’re focused on that.

Growing miniature organ-like tissues in the lab is already within our reach. Now, researchers from Japan have developed a new approach that enables intestinal mini-organs to be grown more easily and efficiently in the lab. This holds immense promise for regenerative medicine.

In a study published in November in Cell Reports Methods, researchers from Tokyo Medical and Dental University (TMDU) reveal that applying a few specialized lab techniques yields intestine-like tissues of predictable size and composition.

Organoids are organ-like balls of cells that are grown in the lab from spheroids (even smaller balls) of and mimic the properties of the organ from which the “seed” cell was taken. Organoids are used for studying organ function in a lab setting and are also promising tools in the field of regenerative medicine.

You can arrange for automatic PayPal payment of Yearly Membership Dues on a Quarterly or Yearly basis AFTER you have filled-in and submitted a membership application and paid the initiation fee which have been received and approved. (You can pay the initiation fee by going to PayPal. From the top menu, select “Personal Send and receive Send Money.” Enter for the email address and make your payment of $75.) Note that when arranging for automatic Quarterly or Yearly payment, the first Quarterly or Yearly payment is made IMMEDIATELY upon arranging for automatic payment.

The artificial intelligence tool, known as FRAN, can make someone look a different age in five seconds.

Researchers at Disney have built an artificial intelligence tool that can make it easier for an actor to appear a different age on screen. Although digital artists can still make necessary modifications to make the effects in a scene look as realistic as possible, the artificial intelligence system can handle most of the aging effects.

Re-aging characters in films using AI

In movies and advertisements, it is costly to create photorealistic digital re-aging and requires artists to go through each scene arduously, frame-by-frame to manually change the character’s appearance and likeness.

A lot of anti-ageing vids lately. Good. This concerns Turn.bio. Though not in this vid, MH does have a habit of asking ‘When?” at some point. Previously Turn.bio said they have a first working treatment in just a few years so we’ll see what happens in vids to come of this interview.


In this video Professor Sebastiano introduces ERA, Epigenetic Reprogramming of Age technology and talks about his thoughts on some of the causes of aging.

Professor Vittorio Sebastiano manages a lab in Stanford University which developed and patented technology for partial cellular reprogramming. He co-founded Turn Bio, where he is now Head of research, to translate this technology into clinical applications. And with that, let me start the interview.

Patrick Burgermeister of KIZOO Technology Ventures presents at Investing in the Age of Longevity 2022. In his talk, Patrick gives an overview of KIZOO Technology Ventures’ investment strategy, with a particular focus on misson-driven investments in early stage companies that open new categories of treatment. Patrick showcases six biotech startups that form part of the company’s key investments: Cellvie, Revel, Cyclarity, LIfT BioSciences, Elastrin, and Mogling Bio.

Download the presentation slides: https://bit.ly/IAL22-Patrick-Burgermeister.

Investing in the Age of Longevity 2022 was held in London on 17 November 2022. The one-day masterclass featured presentations from scientists and business leaders at the cutting edge of the field, giving participants the inside track on the latest aging-related discoveries and investment opportunities.

Download the event programme: https://www.masterinvestor.co.uk/IAL22